Barley Grass Powder

Key Words: Organic barley grass powder；Barley grass juice powder

[Latin Name] Hordeum vulgare L.

[Plant Source] Barley Grass

[Solubility] Free soluble in water

[Appearance] Green fine powder

Plant Part Used: Grass

[Particle size]100 Mesh-200Mesh

[Loss on drying] ≤5.0%

[Heavy Metal] ≤10PPM

[Pesticide residue] EC396-2005, USP 34, EP 8.0, FDA

[Storage] Store in cool & dry area, keep away from the direct light and heat.

[Shelf life] 24 Months

[Package] Packed in paper-drums and two plastic-bags inside.

[Net weight] 25kgs/drum

[What is Barley ?]

Barley is an annual grass. Barley grass is the leaf of the barley plant, as opposed to the grain. It is capable of growing in a wide range of climatic conditions. Barley grass has greater nutritional value if harvested at a young age.

[How does it work?]

The fiber in barley might lower cholesterol and blood pressure in people with high cholesterol. Barley may also reduce blood sugar and insulin levels. Barley seems to slow stomach emptying. This could help keep blood sugar stable and create a sensation of being full, which might help to control appetite.

[Function]

1. Improves energy naturally

2. Rich in antioxidants

3. Improves digestion & regularity

4. Alkalizes the internal body

5. Helps rebuild the immune system

6. Provides raw building blocks for hair, skin and nails

7. Contains detoxification and cleansing properties

8. Contains anti-inflammatory ingredients

9. Promotes clear thinking

10. Has anti-aging properties

very windy day, no rain for 4 weeks and none in sight..Clover was good, grass was excellent but down on bulk….Will the wind stop please …..?

Title: Pneumococcal infections and vaccination.
4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia, Spain

OMICS International: https://omicsonline.org
Vaccine Conferences: https://conferenceseries.com/immunolog…
Global Medical Conferences: https://conferenceseries.com
Global Pharmaceutical Conferences: https://pharmaceuticalconferences.com
Global Cancer Conferences: https://cancersummit.org
Global Diabetes Conferences: https://diabetesexpo.com
Global Dental Conferences: https://dentalcongress.com
Global Nursing Conferences: https://nursingconference.com

Abstract
Pneumococci are major contributors to morbidity and mortality worldwide. They are the major cause of milder respiratory tract infections such as otitis and sinusitis, but also to more severe invasive infections such as community-acquired pneumonia with associated septicemia and meningitis. Even though being a devastating pathogen, pneumococci are also common colonizers of the upper respiratory tract of healthy children where from they may spread to cause disease. Risk groups for acquiring an invasive pneumococcal infection (IPD) include preschool children and the elderly, as well as immunocompromised individuals, splenectomised, and patients with a previous influenza virus infection. Several bacterial virulence factors have been described for pneumococci of which a major one is the capsular polysaccharide. Depending on differences in these capsular structures so far more than 90 different serotypes have been distinguished. Recently so called conjugated vaccines (PCV) have been introduced into the child hood vaccination program in many countries. These vaccines are based on a limited amount (7, 10 or 13) of the capsular serotypes. In Sweden PCVs were introduced in the whole of Sweden year 2009. Vaccine introduction has led to a reduction in the incidence of IPD in vaccinated children but also to serotype replacementand an increase of non-vaccine type disease.

Biography

Birgitta Henriques Normark is professor and head physician in Clinical microbiology at Karolinska Institute and Karolinska University hospital, as well as head physician at the Public Health Agency of Sweden. She is also vice dean for recruitment at Karolinska Institutet and a board member of the Swedish Research Council, Medicine and Health.Her research focuses on epidemiology, antibiotic resistance and host-microbe interactions in bacterial infections with special focus on pneumococcal epidemicity, molecular epidemiology, and mechanisms of invasive disease, innate immunity and host-microbe interactions determining disease outcome. The research has been published in 136 publications of which 107 are original peer reviewed articles.